with tumor invasion and metastasis via Bcl9/9l appear to be dispensable for normal intestinal epithelial homeostasis (Deka et al. 2010) .
In this issue of EBioMedicine, Moor et al. have further investigated the importance of BCL9/9L on WNT signaling in CRC cells (Moor et al. 2015) . They first investigated a second CRC mouse model driven by loss of Apc and oncogenic Kras to complement their initial observations performed on the chemically induced mouse CRC model mentioned above (Deka et al. 2010) confirming that ablation of Bcl9/9l modulates similar alterations of gene expression in both types of tumors with 359 down-and 107 up-regulated common differentially expressed genes. Analysis of the up-and down-regulated genes revealed a negative enrichment of genes related to intestinal WNT targets, stemness and EMT while differentiation-related genes were positively enriched. Interestingly, a search for human homologs allowed the characterization of a BCL9/9L-KO signature of 378 genes that was then used to probe public human CRC databases revealing that hazards of relapse and death are both significantly reduced in patients displaying BCL9/ 9L-KO-like tumor profiles. Then, using the organoid/mini-gut culture system consisting of expanding epithelial stem cells isolated from the intact intestine into three-dimensional structures (Sato and Clevers 2013) , they confirmed that ablation of Bcl9/9l improves morphological differentiation and generates a BCL9/9L KO-like signature without altering proliferation in vitro. Interestingly, subcutaneous grafting of the same organoids in immuno-compromised mice resulted in tumor regression in allografts lacking Bcl9/9l while the wild-type organoids grew exponentially, consistent with their Apc −/− and mutated Kras background. Taken together, these results suggest that CRC cells are very dependent on functional BCL9 proteins for promoting tumor progression via stimulation of stemness and EMT traits and preventing differentiation, a pathway not apparently essential for the maintenance of normal intestinal epithelial homeostasis. The discovery that patients with tumors displaying gene expression profiles similar to the BCL9/ 9L-KO signature have a better prognosis than those with a BCL9/9L wild-type phenotype is quite relevant to these findings. While this points out the interest of the β-catenin-BCL9/9L complex as a potential therapeutic target for CRC, it also raises the need to validate, in the end, the direct implication of BCL9/9L in the generation of the BCL9/9L-KO signature in human cells, considering the fact that BCL9/9L have been found to be expressed in all tumor samples. Another key aspect that remains to be investigated pertains to the possibly distinct implications of BCL9 and BCL9L. The findings from human CRC database analyses that stemness traits appear to correlate much more closely with than BCL9 is noteworthy particularly in the context where in the mouse, BCL9L over-expression appears to induce intestinal tumorigenesis and promote expression of genes involved in EMT (Brembeck et al. 2011) .
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In summary, the results by Moor et al. show that inhibiting the BCL9/ 9L interaction with β-catenin leads to diminished gene expression associated with stemness and EMT traits and promotes differentiation in CRC tumors (in the context as shown previously (Deka et al. 2010) that it remains relatively well tolerated in the normal intestinal epithelium). Taken in conjunction with the fact that the BCL9/9L-KO signature in CRC tumors is associated with a better prognosis, the study points out that the BCL9/9L-β-catenin complex represents a promising potential therapeutic target for treating CRC.
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